- HER2 negative
- ER positive
- PD-L1 positive
- PR positive
- HER2 positive
- ER negative
- PR negative
- EGFR positive
- BRAF positive
- EGFR negative
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- Abiraterone Acetate
- Adequate Treatment Washout Period
- Adjuvant Therapy (except reconstruction)
- Androgen Deprivation
- Androgen Deprivation Therapy (ADT)
- Chemotherapy
- Endocrine Therapy
- Radiation Therapy
- Trastuzumab
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
4041 trials
Trials Without a Placebo
Wilmington, DE (<10 mi)
Waitlist
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if the combination of nab-paclitaxel and gemcitabine can stop tumors from growing in patients whose cancer has come back or did not respond to previous treatments. The study also checks if this combination is safe and tolerable. Nab-paclitaxel (Abraxane) is an albumin-bound paclitaxel that has shown clinical activity in advanced breast and lung cancer and has been tested in combination with gemcitabine for advanced pancreatic cancer, improving response rates and survival.
Efficacy & Safety Awards
No Placebo-Only Group
Reading, PA (<10 mi)
Waitlist
Phase 2
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called IW-3300 to see if it can help people with chronic bladder pain. The drug is given as a rectal foam and aims to relieve symptoms like pain, burning, and pressure. Patients will use the drug at home for a few months.
Reading, PA (<10 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing the addition of radiation therapy to the usual immunotherapy (with or without chemotherapy) treatment for patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (advanced) or has spread to other places in the body (metastatic) and who are also negative for a molecular marker called PD-L1.
Efficacy & Safety Awards
No Placebo-Only Group
Reading, PA (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a 4-drug combo vs. a 3-drug combo to see if the former is more effective in shrinking cancer or preventing its return.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a common cancer treatment alone or with a new drug in patients with advanced lung cancer. The chemotherapy kills cancer cells, and the new drug may help the immune system fight the cancer.
Efficacy & Safety Awards
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying azacitidine with or without nivolumab or midostaurin, or decitabine and cytarabine alone to see how well they work compared to each other in treating patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Efficacy & Safety Awards
No Placebo-Only Group
Reading, PA (<10 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing docetaxel in combination with antiandrogen therapy and radiation therapy versus antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Reading, PA (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing nivolumab with or without ipilimumab to see if it can treat patients with squamous cell lung cancer that has come back after previous treatment.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying whether whole-brain radiation therapy is more effective with or without hippocampal avoidance in treating patients with small cell lung cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Get notified when new Non-Small Cell Lung Cancer trials are postedWe'll send you an email whenever new trials are posted
Reading, PA (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies how well nivolumab works in treating patients with non-small cell lung cancer. Nivolumab is an immunotherapy drug that helps the immune system attack cancer cells. The goal is to see if it can prevent the cancer from coming back. Nivolumab has shown efficacy in treating various malignancies, including non-small cell lung cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying afatinib dimaleate with or without cetuximab to treat patients with non-small cell lung cancer that has EGFR mutations.
Efficacy & Safety Awards
No Placebo-Only Group
Reading, PA (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares erlotinib hydrochloride to observation in treating patients with resected stage IB-IIIA non-small cell lung cancer. Erlotinib hydrochloride may stop tumor cell growth by blocking enzymes needed for cell growth.
Efficacy & Safety Awards
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying the combination of exemestane and entinostat to treat patients with hormone receptor-positive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug for breast cancer patients who have a BRCA1/2 mutation and have completed chemotherapy.
Efficacy & Safety Awards
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying two different combinations of drugs to treat patients with newly diagnosed multiple myeloma.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying hormone therapy with or without everolimus to see how well it works in treating patients with breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying two different radiation therapy regimens to see how well they work in treating patients with early-stage breast cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Reading, PA (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing radiation therapy with cisplatin to radiation therapy with cetuximab to see which is more effective in treating oropharyngeal cancer.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Get notified when new HER2 Positive trials are postedWe'll send you an email whenever new trials are posted
Reading, PA (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying giving chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Reading, PA (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing 4 different hormone therapies with or without chemotherapy to see which is most effective in treating patients with invasive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
1
2
3
…50